73 related articles for article (PubMed ID: 31659661)
21. Direct acting antivirals failure: cause and retreatment options.
Parlati L; Pol S
Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1245-1250. PubMed ID: 30791789
[TBL] [Abstract][Full Text] [Related]
22. The use of technology-based adherence monitoring in the treatment of hepatitis C virus.
Adje YH; Brooks KM; Castillo-Mancilla JR; Wyles DL; Anderson PL; Kiser JJ
Ther Adv Infect Dis; 2022; 9():20499361221095664. PubMed ID: 35591885
[TBL] [Abstract][Full Text] [Related]
23. Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals.
Serper M; Evon DM; Stewart PW; Lok AS; Amador J; Reeve BB; Golin CE; Fried MW; Reddy KR; Sterling RK; Sarkar S; Di Bisceglie AM; Lim JK; Nelson DR; Reau N
J Gen Intern Med; 2020 Apr; 35(4):1011-1020. PubMed ID: 31659661
[TBL] [Abstract][Full Text] [Related]
24. Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada.
Mason K; Dodd Z; Guyton M; Tookey P; Lettner B; Matelski J; Sockalingam S; Altenberg J; Powis J
Int J Drug Policy; 2017 Sep; 47():202-208. PubMed ID: 28619394
[TBL] [Abstract][Full Text] [Related]
25. Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy.
Cartwright EJ; Pierret C; Minassian C; Esserman DA; Tate JP; Goetz MB; Bhattacharya D; Fiellin DA; Justice AC; Lo Re V; Rentsch CT
JAMA Netw Open; 2023 Sep; 6(9):e2335715. PubMed ID: 37751206
[TBL] [Abstract][Full Text] [Related]
26. Virological and Clinical Outcome of DAA Containing Regimens in a Cohort of Patients in Calabria Region (Southern Italy).
Scaglione V; Mazzitelli M; Costa C; Pisani V; Greco G; Serapide F; Lionello R; La Gamba V; Marascio N; Trecarichi EM; Torti C
Medicina (Kaunas); 2020 Feb; 56(3):. PubMed ID: 32121135
[No Abstract] [Full Text] [Related]
27. Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals.
Do A; Esserman DA; Krishnan S; Lim JK; Taddei TH; Hauser RG; Tate JP; Re VL; Justice AC
J Gen Intern Med; 2020 Jul; 35(7):2025-2034. PubMed ID: 32342483
[TBL] [Abstract][Full Text] [Related]
28. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.
Macías J; Morano LE; Téllez F; Granados R; Rivero-Juárez A; Palacios R; Ríos M; Merino D; Pérez-Pérez M; Collado A; Figueruela B; Morano A; Freyre-Carrillo C; Martín JM; Rivero A; García F; Pineda JA;
J Hepatol; 2019 Jul; 71(1):45-51. PubMed ID: 30853642
[TBL] [Abstract][Full Text] [Related]
29. Content Validity and Reliability of a Self-Report Measure of Medication Nonadherence in Hepatitis C Treatment.
Voils CI; King HA; Thorpe CT; Blalock DV; Kronish IM; Reeve BB; Boatright C; Gellad ZF
Dig Dis Sci; 2019 Oct; 64(10):2784-2797. PubMed ID: 31037593
[TBL] [Abstract][Full Text] [Related]
30. Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial.
Akiyama MJ; Norton BL; Arnsten JH; Agyemang L; Heo M; Litwin AH
Ann Intern Med; 2019 May; 170(9):594-603. PubMed ID: 30959528
[TBL] [Abstract][Full Text] [Related]
31. Receipt of alcohol-related care among patients with HCV and unhealthy alcohol use.
Owens MD; Ioannou GN; Tsui JL; Edelman EJ; Greene PA; Williams EC
Drug Alcohol Depend; 2018 Jul; 188():79-85. PubMed ID: 29754030
[TBL] [Abstract][Full Text] [Related]
32. Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies.
Grebely J; Feld JJ; Wyles D; Sulkowski M; Ni L; Llewellyn J; Mir HM; Sajed N; Stamm LM; Hyland RH; McNally J; Brainard DM; Jacobson I; Zeuzem S; Bourlière M; Foster G; Afdhal N; Dore GJ
Open Forum Infect Dis; 2018 Feb; 5(2):ofy001. PubMed ID: 29450210
[TBL] [Abstract][Full Text] [Related]
33. Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy.
Evon DM; Amador J; Stewart P; Reeve BB; Lok AS; Sterling RK; Di Bisceglie AM; Reau N; Serper M; Sarkar S; Lim JK; Golin CE; Fried MW
Aliment Pharmacol Ther; 2018 Apr; 47(7):1001-1011. PubMed ID: 29377191
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of direct-acting antiviral therapy for hepatitis C in difficult-to-treat patients in a safety-net health system: a retrospective cohort study.
Yek C; de la Flor C; Marshall J; Zoellner C; Thompson G; Quirk L; Mayorga C; Turner BJ; Singal AG; Jain MK
BMC Med; 2017 Nov; 15(1):204. PubMed ID: 29151365
[TBL] [Abstract][Full Text] [Related]
35. Barriers to Treatment Access for Chronic Hepatitis C Virus Infection: A Case Series.
Millman AJ; Ntiri-Reid B; Irvin R; Kaufmann MH; Aronsohn A; Duchin JS; Scott JD; Vellozzi C
Top Antivir Med; 2017; 25(3):110-113. PubMed ID: 28820726
[TBL] [Abstract][Full Text] [Related]
36. Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial.
Kattakuzhy S; Gross C; Emmanuel B; Teferi G; Jenkins V; Silk R; Akoth E; Thomas A; Ahmed C; Espinosa M; Price A; Rosenthal E; Tang L; Wilson E; Bentzen S; Masur H; Kottilil S;
Ann Intern Med; 2017 Sep; 167(5):311-318. PubMed ID: 28785771
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
